GastroenteroloGy
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the gastroenterology disease testing capabilities of Mayo Clinic Laboratories, including:
- Inflammatory bowel disease
- Therapeutic drug monitoring
- Intestinal infections
- Chronic liver disease
- Celiac disease
- Pancreatic disease
- Autoimmune testing
- Metabolite monitoring
- Noninvasive mucosal healing tests
- Antibody testing
BioPharma Diagnostics partners can access gastroenterology testing for clinical trials and be among the first to use up-and-coming tests currently in development.
News and updates
The latest
PACE/State of FL - Review known genetic predisposing factors to acute or chronic pancreatitis, as well as define who may benefit from genetic testing.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.
Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients' response to infliximab and adalimumab.
Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic, in this “Specialty Testing” webinar, for a discussion of this testing and its clinical application.
The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.
In this "Hot Topic," Melissa Snyder, Ph.D., provides a brief review of published guidelines for the diagnosis of celiac disease, with a specific focus on the role of laboratory testing.